New study tracks hidden blood condition to prevent future disease

NCT ID NCT07313059

Recruiting now Knowledge-focused Sponsor: Clinical Hub for Interventional Research (CHOIR) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 100 people aged 55 and older who have clonal hematopoiesis (CH) or unexplained low blood counts. Researchers will monitor their health over time, assess risks for heart disease and blood cancers, and provide personalized support. The goal is to create a blueprint for doctors to better care for people with CH and guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could provide a blueprint for monitoring and managing clonal hematopoiesis, potentially reducing risks of blood cancers and heart disease.
What could go wrong: This is an observational study, not a treatment trial. It may not lead to direct medical advances, and results depend on long-term follow-up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CCUS CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clonal hematopoiesis disease hematologic disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CCUS CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE CLONAL HEMATOPOIESIS HEMATOLOGIC DISEASE AND DISORDERS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Canberra Health Services
RECRUITING

Canberra, Australian Capital Territory, 2605, Australia

Contact Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.